Back to News
Market Impact: 0.4
Food Allergy Biotech Firm Lycia Raises $317.5 Million in US IPO
Source: Bloomberg
IPOs & SPACsHealthcare & Biotech
Lycia Therapeutics raised $317.5 million in an upsized U.S. IPO priced at the top of its marketed range. The company focuses on treatments for allergies and autoimmune diseases.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Singapore Feels the Cooling of Asia’s 2026 IPO Party
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Fintech platform OPay files for $336 million U.S. initial public offering
- Oncologists Cheer Melanoma Data
- Will Anthropic pull off a November IPO? Time is running out to file key paperwork.
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors